The Necessity and Optimal Time for Performing Pars Plana Vitrectomy in Acute Retinal Necrosis Patients
Overview
The records of patients who were diagnosed with ARN between April 2010 and February 2017 were analyzed.A retrospective review of the treatment options and outcomes of the these patients was performed.
Study Type
- Study Type: Observational
- Study Design
- Time Perspective: Retrospective
- Study Primary Completion Date: February 2017
Interventions
- Procedure: pars plana vitrectomy
- pars plana vitrectomy
Arms, Groups and Cohorts
- 1
- there was no retinal detachment (RD) at the first visit. The group 1 patients were treated with systemic antiviral medications, as well as with intravitreal antiviral injections
- 2
- there was no RD at the first visit. The group 2 patients were treated with systemic antiviral medications and PPV plus silicone oil tamponade and intravitreal injection.
- 3
- there was RD at the first visit. The group 3 patients were treated with systemic antiviral medications and PPV plus silicone oil tamponade and intravitreal injection
Clinical Trial Outcome Measures
Primary Measures
- visual acuity
- Time Frame: 1 year
Secondary Measures
- retinal detachement
- Time Frame: 1 year
Participating in This Clinical Trial
Inclusion Criteria
- ARN was diagnosed according to the American Uveitis Society Diagnostic Criteria (1994) Exclusion Criteria:
-
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: N/A
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- Chongqing Medical University
- Provider of Information About this Clinical Study
- Principal Investigator: Shulin Liu, Dr. – Chongqing Medical University
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.